Notice of Results
Updated : 07:00
IXICO plc
("IXICO" or the "Company")
Notice of results
Analyst and Investor presentations
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces its audited Final Results for the year ended 30 September 2021 on Tuesday 7 December 2021.
Analyst briefing
A briefing open to analysts will take place remotely via video conference call on Tuesday 7 December 2021 at 9.30am (GMT). If you would like the details of this call please contact Walbrook PR on IXICO@walbrookpr.com
Investor briefing
Giulio Cerroni, CEO, and Grant Nash, CFO, will provide a live presentation relating to the Final Results for the year ended 30 September 2021 via the Investor Meet Company platform on Tuesday 7 December 2021 at 4:30pm (GMT).
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via:
https://www.investormeetcompany.com/ixico-plc/register-investor
Investors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |||
|
| |||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
Giles Balleny / Max Gould (Corporate Finance) |
| |||
Michael F Johnson / Russell Kerr (Sales |
| |||
|
| |||
Walbrook PR Ltd | IXICO@walbrookpr.com | |||
Paul McManus / Lianne Applegarth / | +44 (0)20 7933 8780 | |||
Alice Woodings
|
| |||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.